Results 261 to 270 of about 100,456 (311)

Targeting the microbiota‐miRNA‐protease axis: A new therapeutic avenue in melanoma

open access: yesThe FEBS Journal, EarlyView.
Modulation of extracellular matrix (ECM) turnover is central to melanoma progression and metastasis, driven largely by ECM proteases. This review highlights the epigenetic regulation of ECM proteases by microRNAs and their roles in melanoma growth, invasion, and immune modulation.
Elias N. Katsoulieris   +2 more
wiley   +1 more source

Gastroprotective and Antioxidant Effects of Ferula Plant Extract Against Indomethacin Induced Gastric Ulcer in Rats. [PDF]

open access: yesFood Sci Nutr
Yigit S   +9 more
europepmc   +1 more source

When proteases reshape barriers: Basement membrane remodelling in development, wound healing and tumour progression

open access: yesThe FEBS Journal, EarlyView.
Basement membrane (BM) homeostasis relies on a balance between integrity, controlled remodelling and pathological degradation. Increased protease expression beneath the BM, along with reduced levels of endogenous protease inhibitors, drives the transition from a continuous, protective barrier to a discontinuous interface.
Clara Legendre   +2 more
wiley   +1 more source

Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Acquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan. Aim This post‐marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly
Midori Shima   +8 more
wiley   +1 more source

Small Bowel Lesions and Bleeding Risk in Hemodialysis Patients: A Narrative Review

open access: yesHemodialysis International, EarlyView.
ABSTRACT Background Gastrointestinal bleeding is very common among hemodialysis patients. This high bleeding risk is caused by uremic platelet dysfunction, vascular fragility, intradialytic hemodynamic instability, and widespread antithrombotic therapy.
Andreas Smyrlis   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy